WO1995010280A1 - Modes d'utilisation de derives de la quinoxaline (2 - imidazolin - 2 - ylamino) - Google Patents

Modes d'utilisation de derives de la quinoxaline (2 - imidazolin - 2 - ylamino) Download PDF

Info

Publication number
WO1995010280A1
WO1995010280A1 PCT/US1994/010569 US9410569W WO9510280A1 WO 1995010280 A1 WO1995010280 A1 WO 1995010280A1 US 9410569 W US9410569 W US 9410569W WO 9510280 A1 WO9510280 A1 WO 9510280A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
desired therapeutic
therapeutic effect
radicals containing
reduction
Prior art date
Application number
PCT/US1994/010569
Other languages
English (en)
Inventor
James A. Burke
Michael E. Garst
Larry A. Wheeler
Original Assignee
Allergan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan filed Critical Allergan
Priority to EP94928623A priority Critical patent/EP0723447B1/fr
Priority to JP51181295A priority patent/JP3683908B2/ja
Priority to CA002173974A priority patent/CA2173974C/fr
Priority to AU77988/94A priority patent/AU688380B2/en
Priority to DE69431880T priority patent/DE69431880T2/de
Publication of WO1995010280A1 publication Critical patent/WO1995010280A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention relates to certain derivatives of quinoxaline. More particularly, the invention relates to methods of using such derivatives as therapeutic agents, for example, to effect reduction in peripheral pain, to anesthetize the central nervous system,..* to constrict one or more blood vessels, to treat ischemia, to decongest one or more nasal passages, and to effect reduction of one or more effects of an inflammatory disorder to increase renal fluid flow and to effect an alteration in the rate of fluid transport in the gastrointestinal tract.
  • U.S. Patent 3,890,319 discloses compounds as regulators of the cardiovascular system and, in particular, in the treatment of hypertension, which have the following formula:
  • 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7- or 8- position of the quinoxaline nucleus;
  • X, Y and Z may be in any of the remaining 5-, 6-, 7- or 8- positions and may be selected from hydrogen, halogen, lower alkyl, lower alkoxy or trifluoromethyl;
  • R is an optional substituent in either the 2- or 3- position of the quinoxaline nucleus and may be hydrogen, lower alkyl or lower alkoxy.
  • Gluchowski U.S. Patent 5,021,416 discloses the use of similar quinoxaline derivatives to reduce or maintain the intraocular pressure in a mammalian eye.
  • a desired therapeutic effect is provided in the mammal.
  • desired therapeutic effects include reduction in peripheral pain, anesthetization of the central nervous system, constriction of one or more blood vessels, reduction in or prevention of at least one effect of ischemia, decongestion of one or more nasal passages, reduction in at least one effect of an inflammatory disorder, increase in renal fluid flow, and alteration, preferably decrease, in the rate of fluid transport in the gastrointestinal tract.
  • the quinoxaline derivatives useful in the present invention are ves having the formula
  • R x and R 2 each is independently selected from the group consisting of H, alkyl radicals containing 1 to 4 carbon atoms and alkoxy radicals containing 1 to 4 carbon atoms.
  • R 2 is preferably a methyl radical.
  • the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7- or 8- positions, preferably in the 6- position, of the quinoxaline nucleus.
  • R 3 , R 4 and R s each is located in one of the remaining 5-, 6-, 7- or 8- positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals containing 1 to 3 carbon atoms.
  • R 3 is preferably in the 5- position of the quinoxaline nucleus, and R 4 and R 5 are preferably both H. In a particularly useful embodiment R 3 is Br.
  • R x is H and R 2 is selected from alkyl radicals containing 1 to 4 carbon atoms and alkoxy radicals containing 1 to 4 carbon atoms.
  • R 3 may advantageously be in the 5-position of the quinoxaline nucleus and be selected from H and alkyl radicals containing 1 to 3 carbon atoms.
  • compositions of the invention are those formed from acids which form non-toxic addition salts containing ⁇ pharmaceutically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, sulfate, or bisulfate, phosphate or acid phosphate, acetate, maleate, fumarate, oxalate, lactate, tartrate, citrate, gluconate, saccharate and p-toluene sulphonate salts.
  • pharmaceutically acceptable acid addition salts of the compounds of the invention are those formed from acids which form non-toxic addition salts containing ⁇ pharmaceutically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, sulfate, or bisulfate, phosphate or acid phosphate, acetate, maleate, fumarate, oxalate, lactate, tartrate, citrate, gluconate, saccharate and p-toluene sulphonate salts.
  • the present invention involves methods for treating mammals to provide one or more desired therapeutic effects in the mammal.
  • the present methods comprise administering an effective amount to provide the desired therapeutic effect or effects in a mammal of at least one compound, as described herein, to the mammal.
  • desired therapeutic effects are reduction in peripheral pain, anesthetization of the central nervous system, constriction of one or more blood vessels, reduction in or prevention of at least one effect of ischemia, decongestion of one or more nasal passages, reduction in at least one effect of an inflammatory disorder, for example, such disorders characterized by progressive joint and/or tissue deterioration, increase in renal fluid flow, and alternation, preferably decrease, in the rate of fluid transport in the gastrointestinal tract.
  • the presently useful compounds may be effective as one or more of the following: a peripheral pain killing agent, a general anesthetic, a vaso-constricting agent, an agent for the treatment of ischemia, a nasal decongestant, an anti-inflammatory agent, a medication for use in the treatment or management of kidney disease, and an anti- diarrhea agent.
  • a peripheral pain killing agent e.g., a general anesthetic, a vaso-constricting agent, an agent for the treatment of ischemia, a nasal decongestant, an anti-inflammatory agent, a medication for use in the treatment or management of kidney disease, and an anti- diarrhea agent.
  • a peripheral pain killing agent e.g., a general anesthetic, a vaso-constricting agent, an agent for the treatment of ischemia, a nasal decongestant, an anti-inflammatory agent, a medication for use in the treatment or management of kidney disease, and an anti- diarrhea agent.
  • any suitable method of administering the presently useful compound or compounds to the mammal to be treated may be used.
  • the particular method of administration chosen is preferably one which allows the presently useful compound or compounds to have the desired therapeutic effect in an effective manner, e.g., low medication concentration and low incidence of side effects.
  • the presently useful compound or compounds are administered to a mammal in a manner substantially similar to that used to administer alpha agonists, in particular alpha 2 agonists, to obtain the same or similar therapeutic effect or effects.
  • Administration of the presently useful compounds for use in the methods of this invention can include, but are not limited to, oral, parenteral, topical, intra-articular and other modes of systemic administration.
  • the compounds are administered in a therapeutically effective amount either alone or in combination with a suitable pharmaceutically acceptable carrier or excipient.
  • the presently useful compound or compounds may be incorporated in any pharmaceutically acceptable dosage form, such as for example, tablets, suppositories, pills, capsules, powders, liquids, suspensions, emulsions, aerosols or the like, preferably in unit dosage forms suitable for single administration of precise dosages, or sustained release dosage forms for continuous controlled administration.
  • the dosage form will include a pharmaceutically acceptable excipient and the presently useful compound or compounds and, in addition, may contain other medicinal agents, pharmaceutical agents, carriers, adjutants, etc.
  • non-toxic solid carriers include, but are not limited to, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, the polyalkylene glycols, talcum, cellulose,
  • Liquid pharmaceutically administrable dosage forms can, for example, comprise a solution or suspension of one or more of the presently useful compounds and optional pharmaceutical adjutants in a carrier, such as for example, water, saline, aqueous dextrose, glycerol, ethanol and the like, to thereby form a solution or suspension.
  • a carrier such as for example, water, saline, aqueous dextrose, glycerol, ethanol and the like, to thereby form a solution or suspension.
  • the pharmaceutical composition to be administered may also contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like.
  • auxiliary agents are sodium acetate, sorbitan monolaurate, triethanolamine, sodium acetate, triethanolamine oleate, etc.
  • Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA, 16th Edition, 1980.
  • the composition of the formulation to be administered, in any event contains a quantity of one or more of the presently useful compounds in an amount effective to provide the desired therapeutic effect.
  • Parenteral administration is generally characterized by injection, either subcutaneously, intramuscularly or intravenously.
  • Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol and the like.
  • the injectable pharmaceutical compositions to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying ⁇ agents, pH buffering agents and the like.
  • the amount of the presently useful compound or compounds administered is, of course, dependent on the therapeutic effect or effects desired, on the specific mammal being treated, on the severity and nature of the mammal's condition, on the manner of administration, on the potency and pharmacodynamics of the particular compound or compounds employed, and on the judgement of the prescribing physician.
  • the therapeutically effective dosage of the presently useful compound or compounds is preferably in the range of about 0.5 or about 1 to about 100 mg/kg/day.
  • the presently useful compounds are as described above.
  • the presently useful compounds may be prepared in accordance with the procedures described in Danielewicz, et al U.S. Patent 3,890,319 for the production of the quinoxaline derivatives therein. This patent is hereby incorporated in its entirety by reference herein.
  • the presently useful 2-imidazolin-2-ylamino quinoxaline derivatives may be prepared by (1) reaction of the appropriate amino-quinoxaline with thiophosgene to form the corresponding isothiocyanate; and (2) reacting this isothiocyanate with excess ethylene diamine to form the corresponding beta-aminoethyl-thioureidoquinoxaline, which is then cyclized to the corresponding derivative.
  • such derivatives can be prepared by (1) reacting the corresponding aminoquinoxaline with benzoyl isothiocyanate to form the corresponding N-benzoyl thioureido compound, followed by hydrolysis to the thioureido compound, or reaction of the aminoquinoxaline with ammonium thiocyanate to form the thioureido compound directly; (2) methylation to form the S-methyl derivative of the thioureido compound; and (3) reaction with ethylene diamine to form the derivative.
  • the corresponding bromo derivative can be produced and than subjected to an alkylation reaction in which the bromo group is replaced by the desired alkyl group.
  • This alkylation reaction is conveniently conducted using an alkylation agent, such as an alkyl metallic component, e.g., alkyl stannane, in the presence of a platinum group metal-containing catalyst.
  • an alkylation agent such as an alkyl metallic component, e.g., alkyl stannane
  • a platinum group metal-containing catalyst e.g., platinum group metal-containing catalyst.
  • a palladium-containing catalyst e.g., (Ph 3 P) 2 PdCl 2
  • 6-Aminoquinoxaline (1.00 g, 7.5 mmol) was suspended in 15 ml of water and thiophosgene (0.64 ml, 8.4 mmol) was added in small portions with vigorous stirring. The starting material dissolved and after 2 hours the red color of the solution was discharged. The solid formed was removed by vacuum filtration and washed with water.
  • 6-Aminoquinoxaline (2.08 g, 14.4 mmol) was dissolved in 11.5 ml glacial acetic acid. The solution was cooled in water while a solution of bromine (0.74 ml, 2.3g, 14.4 mmol) in 1.5 ml glacial acetic acid was added slowly over 15 min. After stirring for an additional 30 min, the orange red solid formed was filtered off and washed thoroughly with dry ether. The solid was dried in vacuo overnight to yield 4.44 g crude product (a yield of 100%) . The compound, 6-amino-5-bromoquinoxaline hydrobromide, had no definite melting point. A phase change (from fine powder to red crystals) was noticed at about 220° C. Decomposition was observed at about 245° C. It was used directly for the next step. 6-Amino-5-Bromoquinoxaline
  • the crude 6-amino-5-bromoquinoxaline from above was dissolved in water and saturated sodium bisulfite solution was added until the resulting solution tested negative with starch-iodide paper. The solution was then basified with 2N sodium hydroxide and extracted thoroughly with ethyl acetate. The organic extract was dried over magnesium sulfate and concentrated under reduced pressure to give the free base. The crude product was recrystallized from boiling benzene to give yellow crystals, m.p. 155-6° C. Using various analytical procedures, the yellow crystals were determined to be 6-amino-5-bromoquinoxaline. The yield was 82%.
  • a sealable reaction tube was charged with 5-bromo-6- (2-imidazolin-2-ylamino) quinoxaline (104 mg., 0.36 mmol) (prepared as noted above), tetramethyl tin (214 mg. , 1.2 mmol) and (Ph 3 P) 2 PdCl 2 (10 mg) and dry dimethylformamide (2 ml) in a reaction tube.
  • the reaction mixture was purged with dry nitrogen gas.
  • the tube was sealed and heated to 145° C for 6 hours.
  • the reaction mixture was cooled to room temperature and the solvent removed in vacuo.
  • a thick-walled Parr hydrogenation flask was charged with 2-methyl-6-nitroquinoxaline (10. Og, 52.9) and CH 3 OH (200 ml) .
  • the flask was flushed with a stream of nitrogen and 10% by weight palladium on charcoal (500 mg) was added.
  • the flask was pressurized with hydrogen to 50 psi and maintained at this pressure for three (3) hours.
  • the reaction mixture was filtered and washed through silicon dioxide and concentrated in vacuo to yield a tan solid.
  • 2,3-butanedione (7.03 g, 81.7 mmol) was added to a solution of 1,2,4-triaminobenzene hydrochloride (16.5 g, 81.7 mmol) in aqueous 10% Na 2 C0 3 (200 ml) .
  • the reaction mixture was stirred at room temperature for 15 minutes during which time a yellow precipitate formed.
  • the reaction mixture was stirred for an additional 30 minutes before collecting the solid by vacuum filtration.
  • the solid was washed with water, dried in vacuo and chromatographed (Si0 2 , ethylacetate) to yield 11.7 g (86%) of a tan solid, mp 185-186°C.
  • EXAMPLE 7 The final quinoxaline derivative produced in Example 2, that is 5-bromo-6- (2-imidazolin-2-ylamino)quinoxaline, was tested for central nervous system anesthetization activity as follows.
  • mice hexobarbital sleep time test The first of these animal models is identified generally as the mouse hexobarbital sleep time test. Briefly, the compound in question (in a dosage range of between 10 and 500 micrograms/kg, i.v.) and the barbiturate hexobarbital (75 mg/kg, i.p) are coadministered to mice weighing 20 to 22 grams. The hexobarbital produces sleep which lasts for 10 to 14 minutes. Compounds which have central nervous system anesthetization activity potentiate the sleep time induced by hexobarbital. Sleep time is assessed as the time associated with the loss of the animal's reflex to right itself when placed on its back.
  • the ED 15 is estimated from dose-response data as the effective dose which potentiates sleep time by 15 minutes.
  • the second animal model used is identified generally as the rat activity test. Briefly, rats weighing 140 to 160 grams are placed into an environmentally isolated activity monitor five (5) minutes following administration of the compound in question (in the range of 1 to 1000 micrograms/kg, i.v.) . Horizontal activity, measured in counts is determined for five (5) minutes. A dose-related loss of activity is obtained and fitted to an algorithm to estimate the ID 50 which is the dose which decreases activity by 50%.
  • Example 2 The final quinoxaline derivative produced in Example 2 was tested using both of the above-noted animal models. For comparison purposes, clonidine and its hydrophilic analog, p-amino-clonidine, were also tested using these animal models.
  • Example 2 has substantial central nervous system anesthetization activity.
  • the Example 2 compound has a similar degree of such activity as clonidine, which is known to exhibit significant anesthetization activity, and has substantially more of such activity than the hydrophilic analog of clonidine.
  • New Zealand white rabbits (2-3 kg) are killed by C0 2 inhalation and the vasa deferentia is removed.
  • the prostatic ends of the vasa deferentia (2-3 cm lengths) are mounted between platinum ring electrodes in 9 ml organ baths and bathed in Krebs bicarbonate solution of the following composition (millimolar) : NaCl 118.0; KCl 4.7; CaCl 2 2.5; MgS0 4 1.2; KH 2 P0 4 1.2; glucose 11.0; NaHC0 3 25.0; which solution is maintained at 35° C and bubbled with 95% 0 2 and 5% C0 2 .
  • the initial tension of the vas deferens is 0.5 g.
  • the tissues are left to equilibrate for 30 minutes before stimulation is started.
  • Vasa are then field stimulated (0.1 Hz, 2 ms pulse width at 90 mA) using a square wave stimulator (WPI A310 Accupulser with A385 stimulus) .
  • WPI A310 Accupulser with A385 stimulus The contractions of the tissue are recorded isometrically using Grass FT03 force-displacement transducers and displayed on a Grass Model 7D polygraph.
  • a cumulative concentration-response relationship is obtained for the quinoxaline derivative being tested with a 4 minute contact time at each concentration.
  • Each of the final quinoxaline derivatives of Examples 1 to 5 is effective to reduce the response height. Therefore, such compounds may be properly classified as Alpha 2 agonists since they are also inhibited pharmacologically by treatment with rauwolscine.
  • a rat is placed in the restraining cage, and the arterial line is connected to a Statham pressure transducer and a Beckman Dynograph R61 to monitor the mean arterial blood pressure, hereinafter referred to as MAP.
  • the venous line is connected to an infusion pump system for infusion of replacement fluid.
  • the quinoxaline derivative is administered intraduodenally by cannula.
  • the bladder cannula was extended with a silastic tube to facilitate collection of urine in preweighed tubes. The volume of urine is measured gravimetrically. Body weight is recorded before and after the experiment.
  • Cecectomies are performed in unfasted rats in a conventional manner. The cecectomized rats are put into /10280
  • Diarrhea is induced with oral administration of 16,16-dimethyl prostaglandin E 2 (dmPGE 2 ) in 3.5% EtOH.
  • the quinoxaline derivative is administered by gavage after the onset of diarrheal episodes.
  • the cage papers are removed and examined at 30 minute intervals for dmPGE 2.
  • the fecal output index (FOI) is defined as the summation of the number of defecation episodes and their ranked consistency score within an observation period.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Méthode de traitement de mammifères consistant à leur administrer une dose à effet thérapeutique d'un produit sélectionné parmi ceux d'un groupe de formule (I) et leurs sels d'addition d'acide pharmacocompatibles ou leurs mélanges, où R1 et R2 sont choisis parmi un groupe de radicaux alkyle à 1 à 4 atomes de carbone et parmi un groupe de radicaux alcoxy à 1 à 4 atomes de carbone. Le groupe (2 - imidazolin - 2 - ylamino) peut occuper indifféremment la position 5, 6, 7, 8 dans le noyau de quinoxaline, et R3, R4 et R5 sont chacun situés dans l'une des positions 5, 6, 7 ou 8 restantes du noyau de quinoxaline et sont choisis indépendamment dans le groupe consistant en radicaux Cl, Br, H et alkyle contenant 1 à 3 atomes de carbone. L'administration de ces produits a les effets thérapeutiques escomptés, à savoir: réduction des douleurs périphériques, anesthésie du SNC, constriction d'un ou plusieurs vaisseaux sanguins, atténuation ou prévention d'au moins un des effets de l'ischémie, décongestion des voies nasales, atténuation d'au moins un des effets de troubles d'ordre inflammatoire, accroissement du débit rénal et modification du transit des fluides dans les voies gastro-intestinales.
PCT/US1994/010569 1993-10-13 1994-09-19 Modes d'utilisation de derives de la quinoxaline (2 - imidazolin - 2 - ylamino) WO1995010280A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP94928623A EP0723447B1 (fr) 1993-10-13 1994-09-19 Utilisation de derives de la quinoxaline (2 - imidazolin - 2 - ylamino)
JP51181295A JP3683908B2 (ja) 1993-10-13 1994-09-19 （２−イミダゾリン−２−イルアミノ）キノキサリン誘導体の使用方法
CA002173974A CA2173974C (fr) 1993-10-13 1994-09-19 Modes d'utilisation de derives de la quinoxaline (2 - imidazolin - 2 - ylamino)
AU77988/94A AU688380B2 (en) 1993-10-13 1994-09-19 Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
DE69431880T DE69431880T2 (de) 1993-10-13 1994-09-19 Verwendung von (2-imidazolin-2-yl-amino) quinoxalinderivaten

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13571693A 1993-10-13 1993-10-13
US08/135,716 1993-10-13

Publications (1)

Publication Number Publication Date
WO1995010280A1 true WO1995010280A1 (fr) 1995-04-20

Family

ID=22469328

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/010569 WO1995010280A1 (fr) 1993-10-13 1994-09-19 Modes d'utilisation de derives de la quinoxaline (2 - imidazolin - 2 - ylamino)

Country Status (8)

Country Link
US (7) US5552403A (fr)
EP (2) EP1285657A3 (fr)
JP (3) JP3683908B2 (fr)
AU (1) AU688380B2 (fr)
CA (1) CA2173974C (fr)
DE (1) DE69431880T2 (fr)
ES (1) ES2187533T3 (fr)
WO (1) WO1995010280A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023066A2 (fr) * 1998-10-20 2000-04-27 Omeros Medical Systems, Inc. Solution d'irrigation et procede d'inhibition de la douleur et de l'inflammation
WO2000038684A1 (fr) * 1998-12-30 2000-07-06 Allergan Sales, Inc. Derives de (2-imidazolin-2-ylamino) quinoxaline pour le traitement de la douleur
WO2001060347A2 (fr) * 2000-02-15 2001-08-23 Allergan, Inc. Methode de traitement des douleurs oculaires
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US7973068B2 (en) 1998-10-20 2011-07-05 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
US9254271B2 (en) 1998-10-20 2016-02-09 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
US9744168B2 (en) 2011-10-19 2017-08-29 Galderma Laboratories, Inc. Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors
US9861632B2 (en) 2010-03-26 2018-01-09 Galderma Laboratories, L.P. Methods and compositions for safe and effective treatment of erythema

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100452715B1 (ko) 1995-12-21 2004-12-17 알콘 래보레이토리스, 인코퍼레이티드 녹내장및안구국소빈혈을치료하기위한특정이소퀴놀린술포닐화합물의용도
US6465713B1 (en) * 1997-06-30 2002-10-15 Mcneil-Ppc, Inc. Tampon having an apertured film cover
US6841684B2 (en) 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
US6329369B1 (en) 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
US6242442B1 (en) 1998-12-17 2001-06-05 Alcon Laboratories, Inc. Brinzolamide and brimonidine for treating ocular conditions
MXPA02012206A (es) 2000-07-14 2003-06-04 Allergan Inc Composiciones que contienen componentes terapeuticamente activos que tienen solubilidad mejorada.
US8858961B2 (en) 2000-07-14 2014-10-14 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20040214829A1 (en) * 2000-07-14 2004-10-28 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
CA2402405C (fr) 2000-07-14 2008-02-12 Allergan Sales, Inc. Compositions contenant des composants agonistes alpha-2 adrenergiques
US20050026924A1 (en) * 2000-07-14 2005-02-03 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
ATE444732T1 (de) 2003-08-07 2009-10-15 Allergan Inc Zusammensetzungen zur abgabe von therapeutika in die augen und verfahren zu ihrer herstellung und verwendung
US20070042951A1 (en) * 2003-10-08 2007-02-22 Allergan, Inc. Pharmaceutical compositions comprising alpha-2-adrenergics and trefoil factor family peptides
DE102004024011A1 (de) * 2004-05-14 2005-12-01 Bayer Chemicals Ag Difluorbenzo-1,3-dioxole
ZA200804550B (en) 2005-11-09 2009-08-26 Combinatorx Inc Methods, compositions, and kits for the treatment of medical conditions
US7926280B2 (en) * 2007-05-16 2011-04-19 Pratt & Whitney Canada Corp. Interface between a combustor and fuel nozzle
US20080293728A1 (en) * 2007-05-18 2008-11-27 Mcintire Gregory L Complexes Comprising alpha2-Adrenergic Receptor Agonists and Compositions
US9192571B2 (en) * 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
US7842714B2 (en) * 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
PT2320911E (pt) * 2008-08-01 2014-11-11 Eye Therapies Llc Composições de vasoconstrição e métodos de utilização
US20100202979A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
US20110003823A1 (en) * 2008-08-01 2011-01-06 Alpha Synergy Development, Inc. Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage
US20100197694A1 (en) * 2008-08-01 2010-08-05 Gerald Horn Compositions and methods for treatment of diseases and conditions with increased vascular permeability
US20100203165A1 (en) 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
EP2329849B1 (fr) 2009-11-18 2015-04-29 Galderma Research & Development Combinaison d'un agoniste du récepteur alpha-2 adrénergique et d'un agent anti-inflammatoire non stéroïdien pour traiter ou empêcher un trouble cutané inflammatoire
US8394800B2 (en) 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
KR20130010122A (ko) 2010-03-26 2013-01-25 갈데르마 리써어치 앤드 디벨로프먼트 모세혈관 확장증의 안전하고 유효한 치료를 위한 개선된 방법 및 조성물
AU2011237677A1 (en) 2010-04-07 2012-11-08 Allergan, Inc. Combinations of preservative compositions for ophthalmic formulations
AU2011237689A1 (en) 2010-04-07 2012-11-08 Allergan, Inc. Combinations of preservatives for ophthalmic compositions
ES2498217T5 (es) 2010-10-21 2018-03-19 Galderma S.A. Composición en forma de gel basada en brimonidina
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
KR20140062471A (ko) * 2011-07-25 2014-05-23 알러간, 인코포레이티드 알파 2 아드레날린 수용체의 조절물질로서의 n-(이미다졸리딘-2-일리덴)퀴놀린 유도체

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2309160A1 (de) * 1972-02-29 1973-09-27 Pfizer 2-imidazolin-2-yl-amino-substituierte, benzokondensierte, heterocyclische verbindungen und arzneipraeparate
US4188393A (en) * 1977-04-22 1980-02-12 Sandoz Ltd. Treating spastic conditions or relaxing muscles
EP0422878A1 (fr) * 1989-10-12 1991-04-17 Allergan, Inc. (Imidazoline-2-yl-2-amino)-tetrahydro-quinoxalines et méthodes d'utilisation
EP0426390A2 (fr) * 1989-10-31 1991-05-08 Allergan, Inc. Procédé pour l'utilisation de (2-imidazoline-2-ylamino)-quinoxalines pour réduire ou maintenir la pression intraoculaire
WO1993013771A1 (fr) * 1992-01-13 1993-07-22 Allergan, Inc. Procedes d'utilisation de derives de 2-imidazoline-2-ilamino quinoxaline

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE230960C (fr) *
GB1463520A (en) * 1974-09-06 1977-02-02 Pfizer Ltd Process for the production of imidazolines
US4656291A (en) * 1985-03-15 1987-04-07 Mcneilab, Inc. Process for producing amidine sulfonic acids
US4908387A (en) * 1988-06-06 1990-03-13 The Regents Of The University Of California Use of beta2 antagonists in the treatment of inflammatory diseases, in particular, rheumatoid arthritis
US5034406A (en) * 1989-09-26 1991-07-23 Allergan, Inc. Method for reducing or maintaining intraocular pressure
US5204347A (en) * 1989-10-12 1993-04-20 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) tetrahydroquinoxalines
US5112822A (en) * 1989-10-12 1992-05-12 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5198442A (en) * 1989-10-12 1993-03-30 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5237072A (en) * 1990-02-06 1993-08-17 Allergan, Inc. Method for producing amino-2-imidazoline derivatives
US5130441A (en) * 1990-02-06 1992-07-14 Allergan, Inc. Method for producing amino-2-imidazoline derivatives

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2309160A1 (de) * 1972-02-29 1973-09-27 Pfizer 2-imidazolin-2-yl-amino-substituierte, benzokondensierte, heterocyclische verbindungen und arzneipraeparate
US3890319A (en) * 1972-02-29 1975-06-17 Pfizer (2-imidazolin-2-y(amino) substituted quinolines, -quinoxalines and -quinazolines as antihypertensive agents
US4188393A (en) * 1977-04-22 1980-02-12 Sandoz Ltd. Treating spastic conditions or relaxing muscles
EP0422878A1 (fr) * 1989-10-12 1991-04-17 Allergan, Inc. (Imidazoline-2-yl-2-amino)-tetrahydro-quinoxalines et méthodes d'utilisation
EP0426390A2 (fr) * 1989-10-31 1991-05-08 Allergan, Inc. Procédé pour l'utilisation de (2-imidazoline-2-ylamino)-quinoxalines pour réduire ou maintenir la pression intraoculaire
US5021416A (en) * 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
WO1993013771A1 (fr) * 1992-01-13 1993-07-22 Allergan, Inc. Procedes d'utilisation de derives de 2-imidazoline-2-ilamino quinoxaline

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BERRIDGE TL ET AL: "Characterization of alpha-adrenoceptors in the vasculature of the canine nasal mucosa.", BR J PHARMACOL (ENGLAND), JUN 1986, VOL. 88, NO. 2, PAGE(S) 345-54, *
COLPAERT, FRANCIS C.: "Maximal magnitude of effect and potency of putative.alpha.-adrenoceptor agonists in causing CNS depression, in relaxing muscle, and in lowering body temperature in rat", DRUG DEV. RES., 1986, VOL. 7, PAGE(S) 209-20 *
DHARMSATHAPHORN, KIERTISIN ET AL: "Effects of structure-activity relationships of.alpha.-adrenergic compounds on electrolyte transport in the rabbit ileum and rat colon", GASTROENTEROLOGY, 1984, VOL. 86, PAGE(S) 120-8 *
HAYES, A. G. ET AL: "Alpha-adrenoceptor-mediated antinociception and sedation in the rat and dog", NEUROPHARMACOLOGY, 1986, VOL. 25, PAGE(S) 391-6 *
THAINA P ET AL: "Inhibition by alpha 2-adrenoceptor agonists of contractions of rabbit isolated colon elicited by pelvic nerve stimulation.", J AUTON PHARMACOL (ENGLAND), APR 1993, VOL. 13, NO. 2, PAGE(S) 115-26, *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323204B1 (en) 1993-10-13 2001-11-27 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US8450309B2 (en) 1998-10-20 2013-05-28 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
WO2000023066A3 (fr) * 1998-10-20 2001-08-23 Omeros Med Sys Inc Solution d'irrigation et procede d'inhibition de la douleur et de l'inflammation
US7973068B2 (en) 1998-10-20 2011-07-05 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
WO2000023066A2 (fr) * 1998-10-20 2000-04-27 Omeros Medical Systems, Inc. Solution d'irrigation et procede d'inhibition de la douleur et de l'inflammation
US9254271B2 (en) 1998-10-20 2016-02-09 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
AU764942B2 (en) * 1998-12-30 2003-09-04 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives for the treatment of pain
WO2000038684A1 (fr) * 1998-12-30 2000-07-06 Allergan Sales, Inc. Derives de (2-imidazolin-2-ylamino) quinoxaline pour le traitement de la douleur
WO2001060347A2 (fr) * 2000-02-15 2001-08-23 Allergan, Inc. Methode de traitement des douleurs oculaires
WO2001060347A3 (fr) * 2000-02-15 2002-02-28 Allergan Sales Inc Methode de traitement des douleurs oculaires
US9861632B2 (en) 2010-03-26 2018-01-09 Galderma Laboratories, L.P. Methods and compositions for safe and effective treatment of erythema
US9861631B2 (en) 2010-03-26 2018-01-09 Galderma Laboratories, L.P. Methods and compositions for safe and effective treatment of erythema
US9744168B2 (en) 2011-10-19 2017-08-29 Galderma Laboratories, Inc. Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors

Also Published As

Publication number Publication date
DE69431880T2 (de) 2003-09-18
ES2187533T3 (es) 2003-06-16
JP2005232186A (ja) 2005-09-02
US5561132A (en) 1996-10-01
JP3683908B2 (ja) 2005-08-17
US5756503A (en) 1998-05-26
US5773440A (en) 1998-06-30
US5714486A (en) 1998-02-03
DE69431880D1 (de) 2003-01-23
CA2173974A1 (fr) 1995-04-20
AU688380B2 (en) 1998-03-12
US5552403A (en) 1996-09-03
JP2003277264A (ja) 2003-10-02
JPH09506338A (ja) 1997-06-24
CA2173974C (fr) 2006-05-02
EP0723447A1 (fr) 1996-07-31
AU7798894A (en) 1995-05-04
EP0723447B1 (fr) 2002-12-11
EP1285657A3 (fr) 2003-08-20
US5587376A (en) 1996-12-24
EP1285657A2 (fr) 2003-02-26
US5703077A (en) 1997-12-30

Similar Documents

Publication Publication Date Title
AU688380B2 (en) Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US6323204B1 (en) Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
EP0422878B1 (fr) (Imidazoline-2-yl-2-amino)-tetrahydro-quinoxalines et méthodes d'utilisation
EP0549594A1 (fr) Derives de (2-imidazolin-2-ylamino) quinoxaline et procedes d'utilisation de ces derives.
EP0620732B1 (fr) Procedes d'utilisation de derives de 2-imidazoline-2-ilamino quinoxaline
US5326763A (en) Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5198442A (en) (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5204347A (en) Methods for using (2-imidazolin-2-ylamino) tetrahydroquinoxalines
NZ237076A (en) (2-imidazolin-2-ylamino)-tetrahydroquinoxaline derivatives
IL97220A (en) (2-imidazolin-2-ylamino) tetrahydro-quinoxalines and pharmaceutical compositions comprising them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1994928623

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2173974

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1994928623

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1994928623

Country of ref document: EP